





PHARMACEUTICAL 2023

CTI BIOPHARMA CORP
Rank 356 of 446



The relative strengths and weaknesses of CTI BIOPHARMA CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CTI BIOPHARMA CORP compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 21% points. The greatest weakness of CTI BIOPHARMA CORP is the variable Assets, Current, reducing the Economic Capital Ratio by 75% points.

The company's Economic Capital Ratio, given in the ranking table, is -91%, being 135% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	99,396
Cost of Goods Sold	3,514
Intangible Assets	23,226
Liabilities, Current	81,134
Liabilities, Non-Current	1,234
Other Assets	3,303
Other Compr. Net Income	-35
Other Expenses	8,510
Other Liabilities	61,134
Other Net Income	-13,195
Other Revenues	53,948
Property and Equipment	0
Research and Development	36,895
Selling, General and Administrative Expense	84,826

Output Variable	Value in 1000 USD
Assets	125,925
Liabilities	143,502
Expenses	133,745
Revenues	53,948
Stockholders Equity	-17,577
Net Income	-92,992
Comprehensive Net Income	-93,010
Economic Capital Ratio	-91%